Previous Article | Next Article 
Molecular and Cellular Biology, September 2005, p. 7546-7556, Vol. 25, No. 17
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.17.7546-7556.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity
Jiabin An1 and
Matthew B. Rettig1,2*
Division of Hematology/Oncology, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System West Los Angeles, Los Angeles, California 90073,1
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 900952
Received 24 March 2005/
Returned for modification 26 April 2005/
Accepted 17 June 2005
Biallelic inactivating mutations of the von Hippel-Lindau tumor suppressor gene (VHL) are a hallmark of clear cell renal cell carcinoma (CCRCC), the most common histologic subtype of RCC. Biallelic VHL loss results in accumulation of hypoxia-inducible factor alpha (HIF
). Restoring expression of the wild-type protein encoded by VHL (pVHL) in tumors with biallelic VHL inactivation (VHL/) suppresses tumorigenesis, and pVHL-mediated degradation of HIF
is necessary and sufficient for VHL-mediated tumor suppression. The downstream targets of HIF
that promote renal carcinogenesis have not been completely elucidated. Recently, VHL loss was shown to activate nuclear factor kappa B (NF-
B), a family of transcription factors that promotes tumor growth. Here we show that VHL loss drives NF-
B activation by resulting in HIF
accumulation, which induces expression of transforming growth factor alpha, with consequent activation of an epidermal growth factor receptor/phosphatidylinositol-3-OH kinase/protein kinase B (AKT)/I
B-kinase alpha/NF-
B signaling cascade. We also show that components of this signaling pathway promote the growth of VHL/ tumor cells. Members of this pathway represent viable drug targets in VHL/ tumors, such as those associated with CCRCC.
* Corresponding author. Mailing address: VA Greater Los Angeles Healthcare SystemWest Los Angeles, 11301 Wilshire Blvd., Building 304, Room E1-113, Los Angeles, CA 90073. Phone: (310) 268-3622. Fax: (310) 268-4567. E-mail:
matthew.rettig{at}med.va.gov.
Molecular and Cellular Biology, September 2005, p. 7546-7556, Vol. 25, No. 17
0022-538X/05/$08.00+0 doi:10.1128/MCB.25.17.7546-7556.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Tacchini, L., Gammella, E., De Ponti, C., Recalcati, S., Cairo, G.
(2008). Role of HIF-1 and NF-{kappa}B Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory Signals. J. Biol. Chem.
283: 20674-20686
[Abstract]
[Full Text]
-
Sourbier, C., Danilin, S., Lindner, V., Steger, J., Rothhut, S., Meyer, N., Jacqmin, D., Helwig, J.-J., Lang, H., Massfelder, T.
(2007). Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy. Cancer Res.
67: 11668-11676
[Abstract]
[Full Text]
-
Agouni, A., Sourbier, C., Danilin, S., Rothhut, S., Lindner, V., Jacqmin, D., Helwig, J.-J., Lang, H., Massfelder, T.
(2007). Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B. Carcinogenesis
28: 1893-1901
[Abstract]
[Full Text]
-
Kaelin, W. G. Jr.
(2007). The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma. Clin. Cancer Res.
13: 680s-684s
[Abstract]
[Full Text]
-
An, J., Rettig, M. B.
(2007). Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Molecular Cancer Therapeutics
6: 61-69
[Abstract]
[Full Text]
-
Shioi, K.-i., Komiya, A., Hattori, K., Huang, Y., Sano, F., Murakami, T., Nakaigawa, N., Kishida, T., Kubota, Y., Nagashima, Y., Yao, M.
(2006). Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients. Clin. Cancer Res.
12: 7339-7346
[Abstract]
[Full Text]
-
Ahmed, K. M., Dong, S., Fan, M., Li, J. J.
(2006). Nuclear Factor-{kappa}B p65 Inhibits Mitogen-Activated Protein Kinase Signaling Pathway in Radioresistant Breast Cancer Cells. Mol Cancer Res
4: 945-955
[Abstract]
[Full Text]
-
Cummins, E. P., Berra, E., Comerford, K. M., Ginouves, A., Fitzgerald, K. T., Seeballuck, F., Godson, C., Nielsen, J. E., Moynagh, P., Pouyssegur, J., Taylor, C. T.
(2006). Prolyl hydroxylase-1 negatively regulates I{kappa}B kinase-beta, giving insight into hypoxia-induced NF{kappa}B activity. Proc. Natl. Acad. Sci. USA
103: 18154-18159
[Abstract]
[Full Text]
-
Hwang, I. I. L., Watson, I. R., Der, S. D., Ohh, M.
(2006). Loss of VHL Confers Hypoxia-Inducible Factor (HIF)-Dependent Resistance to Vesicular Stomatitis Virus: Role of HIF in Antiviral Response. J. Virol.
80: 10712-10723
[Abstract]
[Full Text]